依降钙素联合藤黄健骨胶囊治疗骨质疏松症患者的疗效及对患者骨密度、骨代谢的影响<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2025.04.002

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1214 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨依降钙素联合藤黄健骨胶囊治疗骨质疏松症(OP)患者的疗效及对患者骨密度、骨代谢的影响。【方法】选取2022年1月至2023年1月本院收治的100例OP患者,按随机数字表法分为对照组(给予依降钙素治疗)和观察组(给予依降钙素联合藤黄健骨胶囊治疗),每组50例。比较两组疗效、骨密度、骨矿含量、骨代谢生化指标、炎症指标。【结果】观察组总有效率为90.00%,高于对照组的74.00%,差异有统计学意义(P<0.05)。治疗后,两组股骨颈骨密度、腰椎骨密度、股骨颈骨矿含量、腰椎骨矿含量及骨特异性碱性磷酸酶(BALP)、骨钙素、降钙素水平高于治疗前,且观察组高于对照组(P<0.05)。治疗后,两组β-Ⅰ型胶原交联C-末端肽(β-CTX)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平低于治疗前,且观察组低于对照组(P<0.05)。【结论】依降钙素联合藤黄健骨胶囊治疗OP患者,可显著提高临床疗效、骨矿含量,改善骨密度、骨代谢生化指标、炎症指标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	邓方玉
	邝高艳
	邝涛

关键词 ：骨质疏松, 降钙素, 藤黄健骨胶囊, 骨密度, 骨和骨组织

Abstract：【Objective】To investigate the efficacy of calcitonin combined with Tenghuang Jiangu capsule in the treatment of osteoporosis (OP) patients and its influence on bone mineral density and bone metabolism. 【Methods】A total of 100 OP patients admitted to our hospital from January 2022 to January 2023 were divided into the control group (treated with calcitonin) and the observation group (treated with calcitonin combined with tenghuang jiangu capsule) according to random number table, with 50 cases in each group. The therapeutic effect, bone mineral density, bone metabolic biochemical indexes and inflammatory indexes were compared between the two groups. 【Results】The total effective rate of the observation group was 90.00%, which was higher than that of control group (74.00%), the difference was statistically significant (P<0.05). After treatment, bone mineral density of femoral neck, lumbar vertebra bone density, bone mineral content of femoral neck, lumbar vertebra bone mineral content, bone-specific alkaline phosphatase (BALP), osteocalcin and calcitonin in two groups were higher than those before treatment, and these measurement levels in the observation group were higher than those in the control group (P<0.05). After treatment, the β-typeⅠcollagen carboxy-terminal peptide (β-CTX), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in the two groups were lower than those before treatment, and the levels of the observation group were lower than those of the control group (P<0.05). 【Conclusion】In the treatment of OP patients, calcitonin combined with Tenghuang Jiangu capsule can significantly improve clinical efficacy, bone mineral content, bone mineral density, biochemical indexes of bone metabolism and inflammatory indexes.

Key words： Osteoporosis Calcitonin Tenghuang Jiangu Capsule Bone Density Bone and Bones

收稿日期: 2025-03-18

中图分类号:

R68

基金资助:^*湖南省自然科学基金(2023JJ30471);湖南省中医药管理局课题(B2024046);2023年度湖南省教育厅科学研究项目(23A0286);长沙市自然科学基金(kq2403107)

通讯作者: ^**E-mail:995711640@qq.com

引用本文:

邓方玉, 邝高艳, 邝涛. 依降钙素联合藤黄健骨胶囊治疗骨质疏松症患者的疗效及对患者骨密度、骨代谢的影响^*[J]. 医学临床研究, 2025, 42(4): 564-566.
DENG Fangyu, KUANG Gaoyan, KUANG Tao. Effect of Calcitonin Combined with Tenghuang Jiangu Capsule on Bone Mineral Density and Bone Metabolism in Treatment of Patients with Osteoporosis. JOURNAL OF CLINICAL RESEARCH, 2025, 42(4): 564-566.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2025.04.002 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2025/V42/I4/564

[1] COSMAN F, LANGDAHL B, LEDER B Z. Treatment sequence for osteoporosis[J].Endocr Pract,2024,30(5):490.
[2] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J].中国全科医学,2023,26(14):1671-1691.
[3] 陈学青,张英剑,商福青. 阿仑膦酸钠片联合依降钙素对骨质疏松骨折患者术后骨痛的影响[J].中国临床药理学杂志,2021,37(9):1059-1062.
[4] 胡得翼,鄢卫平,李景周,等. 基于“肾虚血瘀”理论探讨骨质疏松症的病因病机及治疗现状[J].风湿病与关节炎,2023,12(11):44-47.
[5] 周霖,王肖辉,孙志,等. 藤黄健骨胶囊质控成分定量分析方法建立及潜在作用机制预测[J].中国药房,2022,33(22):2743-2747.
[6] 邱敏丽,谢雅,王晓红,等. 骨质疏松症患者实践指南[J].中华内科杂志,2020,59(12):953-959.
[7] 中华医学会放射学分会骨关节学组,中国医师协会放射医师分会肌骨学组,中华医学会骨科学分会骨质疏松学组,等. 骨质疏松的影像学与骨密度诊断专家共识[J].中国骨质疏松杂志,2020,26(9):1249-1256.
[8] 中国老年学和老年医学学会骨质疏松分会中医药专家委员会,葛继荣,王和鸣,等. 中医药防治原发性骨质疏松症专家共识(2020)[J].中国骨质疏松杂志,2020,26(12):1717-1725.
[9] 冯宜蒀,来积芳,董万涛,等. 基于网络药理学的“淫羊藿-熟地黄”配伍治疗骨质疏松症作用机制研究[J].中国骨质疏松杂志,2021,27(6):875-881.
[10] 雷蒙蒙. 鹿衔草的新化学成分与提取工艺研究进展[J].微量元素与健康研究,2018,35(3):43-45.
[11] 梁炎丽,梁洁,孙正伊,等. 鸡血藤的质量控制现状及质量标志物预测分析[J].中华中医药学刊,2024,42(5):125-130.
[12] 许诺,高明利. 莱菔及莱菔子的药理作用及临床应用研究进展[J].辽宁中医药大学学报,2024,26(7):60-67.
[13] 肖平,侯平,林正坚,等. 淫羊藿总黄酮和戊酸雌二醇对骨质疏松症大鼠TGF-β1/Smads信号通路的影响[J].中国骨质疏松杂志,2022,28(6):818-824.
[14] 郑玉玲,李纳纳,冯京,等. 肉苁蓉苯乙醇苷类成分抗骨质疏松作用机制研究进展[J].天津中医药大学学报,2022,41(2):265-272.
[15] 刘博,丁龙龙,陈志健,等. 骨碎补及其活性成分防治骨质疏松症的作用机制[J].中国骨质疏松杂志,2024,30(10):1540-1547.
[16] 张晏宁,朱崇田. 藤黄健骨胶囊对膝骨关节炎鼠骨代谢指标及PI3K/Akt/Nrf2/HO-1信号通路的影响[J].世界中西医结合杂志,2024,19(4):694-698.
[17] WANG T T, YU X J, HE C Q. Pro-inflammatory cytokines: cellular and molecular drug targets for glucocorticoid-induced-osteoporosis via osteocyte[J].Curr Drug Targets,2019,20(1):1-15.
[18] 符仲秋,王维学,丰景斌. 藤黄健骨胶囊对大鼠膝骨关节炎的影响[J].中国临床药理学杂志,2021,37(15):1996-1998.